• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Allscripts Swallows Poison Pill to Avoid Hostile Takeover

by Fred Pennic 05/07/2012 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

poison-pill Allscripts Healthcare Solutions, Inc. announced on Monday adopted a shareholder rights plan, also commonly called a “poison pill” to protect itself from any potential hostile takeover approaches in the wake of firing the chairman and departure of three board members that sent its stock price tumbling 34% since April 26. The New York Hedge Fund that holds 4.9% of the company along with other large shareholders demanded the resignation of CEO Glen Tullman citing  weak forecast reporting a 54% decline in first quarter profits and issues with the execution of integrating Eclipsys Corp, the software vendor that it bought two years ago for $1.3 billion in stock.

Under the shareholder rights plan, stockholders will receive rights to purchase shares of a new series of preferred stock in certain circumstances. The rights will be exercisable if a person or group, without board approval, acquires 10% or more of Allscripts’ common stock. The plan exempts any person or group already owning 10% or more of Allscripts’ shares, but it may be exercisable if they acquire any additional shares. The plan will expire May 6, 2013.

In a Monday statement, newly named Chairman Dennis Chookaszian said the board believes that the current share price does not reflect the company’s long-term potential. Chookaszian said the anti-takeover measure was “a temporary measure that is consistent with the board’s fiduciary duties.”

 

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Allscripts

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |